O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+17.87%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$5.42B
AUM Growth
+$5.42B
(+22%)
Cap. Flow
+$335M
Cap. Flow
% of AUM
6.18%
Top 10 Holdings %
Top 10 Hldgs %
41.42%
Holding
137
New
14
Increased
37
Reduced
30
Closed
15
Top Buys
| 1 |
Merck
MRK
|
$92.9M |
| 2 |
Bristol-Myers Squibb
BMY
|
$87.1M |
| 3 |
SHPG
Shire pic
SHPG
|
$82.8M |
| 4 |
CBST
CUBIST PHARMACEUTICALS INC
CBST
|
$51.7M |
| 5 |
Exelixis
EXEL
|
$50.9M |
Top Sells
| 1 |
ONXX
ONYX PHARMACEUTICALS INC
ONXX
|
$102M |
| 2 |
Incyte
INCY
|
$43.2M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
$26.9M |
| 4 |
MAKO
MAKO SURGICAL CORP COM
MAKO
|
$26.7M |
| 5 |
Pfizer
PFE
|
$25.6M |
Sector Composition
| 1 | Healthcare | 86.37% |
| 2 | Financials | 1.83% |
| 3 | Technology | 0.15% |
| 4 | Utilities | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Vanda Pharmaceuticals
VNDA
$279M
| – | – |
0
| – | – |
|
127
SPDR S&P Biotech ETF
XBI
$5.29B
| – | – |
0
| – | – |
|
128
Zoetis
ZTS
$67.6B
| – | – |
-131,732
| Closed | -$4.07M |
|
|
ONCT
129
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| – | – |
0
| – | – |
|
|
SGEN
130
DELISTED
Seagen Inc. Common Stock
SGEN
| – | – |
0
| – | – |
|
|
NTUS
131
DELISTED
Natus Medical Inc
NTUS
| – | – |
-1,427,000
| Closed | -$19.5M |
|
|
ACHN
132
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| – | – |
-545,000
| Closed | -$4.46M |
|
|
ECYT
133
DELISTED
Endocyte, Inc. Common Stock
ECYT
| – | – |
-662,000
| Closed | -$8.69M |
|